Phylo partners with Bayer to use AI platform for drug discovery research

Phylo, Inc. announced on October 22 a partnership with Bayer to use its Biomni Lab artificial intelligence platform in drug-discovery research, according to EconoTimes.

The Biomni Lab platform is designed to help Bayer researchers assemble scientific literature and omics evidence, aiming to reduce manual work in gathering and assessing information.

The announcement stated Bayer would receive full access to the platform, but it was unclear whether Bayer had already begun using Biomni Lab or when a rollout might occur.

Phylo did not disclose financial terms, specific research teams involved, or deployment details, nor did it provide performance results or metrics related to the platform's impact on Bayer's research pace or outcomes.

The platform allows researchers to inspect evidence and analytical steps associated with outputs, integrating research papers, biomedical data, and analysis tools for drug-discovery workflows.